Ceptur Therapeutics Overview

  • Year Founded
  • 2008

Year Founded

  • Status
  • Private

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $75M

  • Investors
  • 11

Ceptur Therapeutics General Information

Description

Developer of U1 adaptor technology designed to facilitate the creation of treatment. The company's technology overcomes the limitations of gene silencing technologies and offers cancer treatment, enabling doctors to treat patients with various types of cancers.

Contact Information

Formerly Known As
Silagene
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1 Ilene Court, Building 8
  • Suite 9
  • Hillsborough, NJ 08844
  • United States
+1 (908)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1 Ilene Court, Building 8
  • Suite 9
  • Hillsborough, NJ 08844
  • United States
+1 (908)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ceptur Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A) 19-Jan-2022 $75M Completed Generating Revenue
2. Seed Round 13-Aug-2020 Completed Clinical Trials - Phase 1
1. Grant 01-Jan-2010 $189K Completed Startup
To view Ceptur Therapeutics’s complete valuation and funding history, request access »

Ceptur Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Ceptur Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Ceptur Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of U1 adaptor technology designed to facilitate the creation of treatment. The company's technology overcomes
Drug Discovery
Hillsborough, NJ
6 As of 2023

NC
 

Brisbane, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ceptur Therapeutics Competitors (3)

One of Ceptur Therapeutics’s 3 competitors is GeneCentric, a Venture Capital-Backed company based in NC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GeneCentric Venture Capital-Backed NC
ReviR Therapeutics Venture Capital-Backed Brisbane, CA
Arrakis Therapeutics Venture Capital-Backed Waltham, MA
You’re viewing 3 of 3 competitors. Get the full list »

Ceptur Therapeutics Patents

Ceptur Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3946375-A1 Compositions and methods for treating neurodegenerative disorders Inactive 26-Mar-2019
AU-2020248392-A1 Compositions and methods for treating neurodegenerative disorders Inactive 26-Mar-2019
US-20220372488-A1 Compositions and methods for treating neurodegenerative disorders Pending 26-Mar-2019
CA-3134683-A1 Compositions and methods for treating neurodegenerative disorders Pending 26-Mar-2019
EP-3935167-A2 Compositions and methods for treating huntington's disease Inactive 08-Mar-2019 C12N15/113
To view Ceptur Therapeutics’s complete patent history, request access »

Ceptur Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ceptur Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bristol-Myers Squibb Corporation Minority
Janus Henderson Investors Asset Manager Minority
Perceptive Advisors Venture Capital Minority
Qiming Venture Partners USA Venture Capital Minority
venBio Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

Ceptur Therapeutics FAQs

  • When was Ceptur Therapeutics founded?

    Ceptur Therapeutics was founded in 2008.

  • Where is Ceptur Therapeutics headquartered?

    Ceptur Therapeutics is headquartered in Hillsborough, NJ.

  • What is the size of Ceptur Therapeutics?

    Ceptur Therapeutics has 6 total employees.

  • What industry is Ceptur Therapeutics in?

    Ceptur Therapeutics’s primary industry is Drug Discovery.

  • Is Ceptur Therapeutics a private or public company?

    Ceptur Therapeutics is a Private company.

  • What is Ceptur Therapeutics’s current revenue?

    The current revenue for Ceptur Therapeutics is .

  • How much funding has Ceptur Therapeutics raised over time?

    Ceptur Therapeutics has raised $81.2M.

  • Who are Ceptur Therapeutics’s investors?

    Bristol-Myers Squibb, Janus Henderson Investors, Perceptive Advisors, Qiming Venture Partners USA, and venBio are 5 of 11 investors who have invested in Ceptur Therapeutics.

  • Who are Ceptur Therapeutics’s competitors?

    GeneCentric, ReviR Therapeutics, and Arrakis Therapeutics are competitors of Ceptur Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »